Current perspectives on biosimilars

In this work, an overview of the biosimilars market, pipeline and industry targets is discussed. Biosimilars typically have a shorter timeline for approval (8 years) compared to 12 years for innovator drugs and the development cost can be 10–20% of the innovator drug. The biosimilar pipeline is revi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Ind Microbiol Biotechnol
Main Authors: Agbogbo, Frank K., Ecker, Dawn M., Farrand, Allison, Han, Kevin, Khoury, Antoine, Martin, Aaron, McCool, Jesse, Rasche, Ulrike, Rau, Tiffany D., Schmidt, David, Sha, Ma, Treuheit, Nicholas
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Fermentation, Cell Culture and Bioengineering - Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6791907/
https://ncbi.nlm.nih.gov/pubmed/31317293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10295-019-02216-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados